Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effects of TQH3906 Capsules in adults with active Psoriatic Arthritis PsA. The study plans to enroll 156 participants to assess how different doses of TQH3906 compare to placebo in improving PsA symptoms at Week 12, focusing on the proportion of participants reaching a 20% improvement according to the American College of Rheumatology criteria. Participants will be randomly assigned to receive one of several oral treatments daily from Day 1 to Day 169. These include 24 mg or 16 mg doses of TQH3906 capsules, a placebo phase followed by TQH3906, or an active comparator, Tofacitinib Citrate tablets. The study uses a double-blind design to compare these treatments effects and safety. Throughout the study, participants will attend visits for assessments including the ACR improvement criteria at multiple time points up to Day 169. Blood samples will be collected to evaluate drug levels and immune markers, and safety will be monitored closely. The main outcome is the proportion of participants achieving ACR20 response at Week 12. The study duration extends up to November 2027, with detailed evaluations of drug effects and adverse events throughout.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are comparing two treatment combinations for elderly patients with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant initially. The study evaluates the safety and effectiveness of daratumumab, lenalidomide, and dexamethasone DRd versus a modified combination of bortezomib, lenalidomide, and dexamethasone VRd-lite. The main goals are to see which treatment better delays disease progression and achieves a negative minimal residual disease status. Participants can choose between the two treatments. Daratumumab is given through weekly intravenous infusions initially, then less frequently over several months, combined with oral lenalidomide and dexamethasone taken on specific days in 28-day cycles. The alternative group receives bortezomib injections weekly with the same oral medications on a similar schedule. After the initial treatment cycles, maintenance therapy continues with lenalidomide alone or combined with daratumumab or bortezomib based on risk assessment until disease progression or unacceptable side effects occur. During the study, participants will be regularly monitored for disease progression and safety, with evaluations including progression-free survival and minimal residual disease negativity measured at multiple timepoints over approximately five years. Additional response rates and overall survival will also be tracked. Safety assessments continue throughout the study to ensure participant well-being during treatment and follow-up.
Actively Recruiting
Researchers are studying the safety and effectiveness of TQB2102 for injection in patients with HER2-positive biliary tract cancer. This includes patients with locally advanced or metastatic forms of the disease who have experienced failure of 1-2 prior systemic therapies. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and spans phases 1 and 2 to evaluate dosing, safety, and immune response. Participants receive TQB2102, a HER2 dual-antibody-drug conjugate, by intravenous infusion every three weeks in cycles of 21 days. Treatment involves 6 to 8 cycles, with ongoing monitoring for adverse events and response to therapy. The study does not use masking or placebo controls. During the trial, participants undergo assessments for tumor response, disease control, survival, and side effects from the time of consent until 28 days after the last dose or the start of a new antitumor therapy. Follow-up includes evaluations up to 36 weeks for outcomes like progression-free and overall survival. Participants also provide tumor tissue samples for HER2 testing and are monitored for immune reactions and safety throughout the study.
Actively Recruiting
Researchers are evaluating the safety and activity of vedolizumab intravenous infusion as a treatment for adults in China with moderately to severely active Crohns Disease. This phase 3 study involves about 408 participants and compares vedolizumab with a placebo during a 14-week induction period. The study aims to assess clinical response and remission, as well as endoscopic response, to understand how vedolizumab works for this condition. Participants will receive vedolizumab 300 mg intravenous infusions at Weeks 0, 2, and 6 during the induction period, or placebo infusions on the same schedule. After Week 14, all participants continue in an open-label extension period receiving vedolizumab every 8 weeks. From Week 18 onward, those who do not respond well or whose disease worsens may receive vedolizumab every 4 weeks. This treatment phase lasts about 58 weeks. During the study, participants will attend up to 20 visits for assessments including clinical evaluations, endoscopic exams, and safety monitoring. Researchers will track clinical response, remission, adverse events, laboratory results, and vital signs through Week 14 and up to 18 weeks after the last dose. A final safety follow-up occurs 18 weeks after the last dose, and a long-term safety survey is conducted six months later via telephone. Overall, participants will be involved in the study for approximately 58 weeks plus follow-up periods.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating a telemedicine-supported, village doctor-led integrated management model for older adults aged 65 to 80 years living in rural China who have both atrial fibrillation AF and heart failure HF. The study aims to see if this integrated care approach, which follows the AF-HF comorbidity ABC pathway and includes enhanced patient education, improves clinical outcomes compared to usual care. The trial is designed as a cluster-randomized, open-label, parallel-group clinical trial involving village clinics in Jiangsu Province. Participants will be divided into two groups. One group receives village-doctor-led integrated care that includes monthly follow-up visits, symptom and vital sign monitoring, medication reviews, guideline-based management, specialist consultation when needed via telemedicine, and structured patient education. The control group receives usual chronic disease management according to Chinas National Basic Public Health Service. The trial has three phases an initial 12-month phase evaluating changes in the MAGGIC heart failure risk score, a 36-month phase assessing a composite cardiovascular endpoint, and an extended observational follow-up at 6 years to evaluate long-term effects. Throughout the study, participants will have regular assessments including clinical status, vital signs, ECG, medication adherence, and risk factor monitoring. Researchers will track outcomes such as cardiovascular death, stroke, hospitalizations, emergency visits, and adherence to guideline-recommended therapy. Patient education will be reinforced monthly with face-to-face sessions, reminders, and brochures. The total follow-up time for participants can extend up to 72 months, allowing for evaluation of both short- and long-term management of AF with HF in a rural setting.
Actively Recruiting
Researchers are evaluating a telehealth-supported, village doctor-led integrated care program compared to usual care to improve cardiovascular health and prevent heart failure in older adults with atrial fibrillation living in rural China. This study focuses on older patients aged 65 to 80 years without prior heart failure and aims to improve AF management, self-care adherence, and reduce cardiovascular complications over several years. Participants in the intervention group will receive monthly follow-ups by village doctors, symptom and vital sign monitoring, medication support, cardiovascular risk management, guideline-based AF care following the ABC pathway, simplified exercise rehabilitation, and remote specialist consultation via telemedicine. Village doctors will be trained in stroke prevention, anticoagulation, symptom control, and risk factor management. The control group will receive usual chronic disease care according to national public health guidelines without the structured integrated program. Participants will be monitored for up to 7 years, with key assessments at 12, 36, 48, and 84 months. Researchers will track changes in cardiovascular health scores, composite cardiovascular events, new heart failure diagnoses, and adherence to guideline-based AF care. Evaluations include symptom assessments, ECGs, risk factor monitoring, and emergency visits. The study includes long-term follow-up to assess the sustained impact of the intervention on heart failure prevention and cardiovascular outcomes.
Actively Recruiting
Researchers are investigating acute aortic syndrome AAS, a serious and life-threatening heart condition where inflammation plays a significant role in its development and progression. This large observational study involves 20 cardiovascular centers in China collaborating to understand inflammatory responses and anti-inflammatory treatments in patients undergoing surgery for AAS. The study aims to assess how inflammation and anti-inflammatory strategies affect patient outcomes after surgery, including complications and survival. The study enrolls adult patients who have undergone surgery for AAS, which includes various types of aortic injuries such as dissection, penetrating ulcers, or hematomas. Participants may have received medical therapy, open surgery, endovascular repair, or hybrid procedures, sometimes combined with other cardiac surgeries. Data about their inflammatory responses and clinical results are collected through designed forms and analyzed using statistical software. This observational study began in 2016 and will continue enrolling patients until 2040. Participants will be followed over time to evaluate key outcomes like severe inflammatory reactions within 7 days after surgery and operative mortality within 30 days. Researchers will also monitor other complications such as organ dysfunction, stroke, kidney injury, infections, bleeding, and length of intensive care stay. The study gathers detailed information through clinical data collection and monitors these outcomes to better understand and improve management for patients with AAS over the long term.
1-10 of 25
1